Article Details
Retrieved on: 2018-01-02 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively modulate growth factor activation in the disease microenvironment, today announced the closing of a $47 million Series C financing. The financing was led by ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here